SciLifeLab
Browse

Plasma proteomics in two Swedish cohorts with Ovarian Cancer

dataset
posted on 2025-04-04, 08:24 authored by Mikaela MoskovMikaela Moskov, Julia Hedlund Lindberg, Maria Lycke, Emma Ivansson, Ulf Gyllensten, Karin Sundfeldt, Karin Stålberg, Stefan EnrothStefan Enroth

The plasma proteome was analyzed using the proximity extension assay (PEA) as implemented in the Explore HT-version (Olink Proteomics AB, Uppsala, Sweden). The samples were analyzed at the Olink Service Laboratory in Uppsala, Sweden. In brief, the PEA is based on pairs of antibodies equipped with probes, DNA single-strand oligonucleotide reporter molecules, that bind to their respective target if present. Target binding by both probes in close proximity generates double-stranded DNA amplicons which are then quantified by next generation sequencing. Here, 5416 unique proteins were characterized in each of the 404 samples. The samples were randomized across plates with respect to cohort and diagnose (benign or malignant). In the resulting data-file provided by the analysis platform, each individual protein measurement, assay and sample is labelled depending on passing or failing quality control as provided by the instrument software. Here, a total on 768 individual measurements (corresponding to 0.036%, 768/(404*5416)) did not pass quality control and were removed from further analyses. Two proteins (apolipoprotein E (APOE) and fibronektin 1 (FN1)) had detection rates below 95% across all samples and were removed from further analyses. The resulting NPX values are on a log2 scale and in the logarithmic phase of the curve, one (1) increase of the NPX value corresponds to a doubling of the protein content. In the resulting data, a high NPX value corresponds to a high protein concentration. Each of the measured proteins has a lower limit of detection (LOD) given in the same NPX-scale which is determined at run time. Here, measurements under LOD were kept as is in the downstream analysis. After quality control, the detection rate across all samples were 99.5 to 99.8%.

Funding

Multi-omics characterization of tumour-tissue, plasma and cervicovaginal fluid for early detection of ovarian cancer

Swedish Research Council

Find out more...

The Swedish Cancer Foundation 220604FE

The Swedish Cancer Foundation 232874PJ

The Swedish Cancer Foundation 190008PJ

The Swedish Cancer Foundation CAN211848

The Swedish state under the agreement between the Swedish government and the county council, the ALF-agreement

History

Publisher

Uppsala University

Access request email

stefan.enroth@igp.uu.se

Usage metrics

    Science for Life Laboratory

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC